Cargando…

Discovery and validation of breast cancer subtypes

BACKGROUND: Previous studies demonstrated breast cancer tumor tissue samples could be classified into different subtypes based upon DNA microarray profiles. The most recent study presented evidence for the existence of five different subtypes: normal breast-like, basal, luminal A, luminal B, and ERB...

Descripción completa

Detalles Bibliográficos
Autores principales: Kapp, Amy V, Jeffrey, Stefanie S, Langerød, Anita, Børresen-Dale, Anne-Lise, Han, Wonshik, Noh, Dong-Young, Bukholm, Ida RK, Nicolau, Monica, Brown, Patrick O, Tibshirani, Robert
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1574316/
https://www.ncbi.nlm.nih.gov/pubmed/16965636
http://dx.doi.org/10.1186/1471-2164-7-231
_version_ 1782130284488032256
author Kapp, Amy V
Jeffrey, Stefanie S
Langerød, Anita
Børresen-Dale, Anne-Lise
Han, Wonshik
Noh, Dong-Young
Bukholm, Ida RK
Nicolau, Monica
Brown, Patrick O
Tibshirani, Robert
author_facet Kapp, Amy V
Jeffrey, Stefanie S
Langerød, Anita
Børresen-Dale, Anne-Lise
Han, Wonshik
Noh, Dong-Young
Bukholm, Ida RK
Nicolau, Monica
Brown, Patrick O
Tibshirani, Robert
author_sort Kapp, Amy V
collection PubMed
description BACKGROUND: Previous studies demonstrated breast cancer tumor tissue samples could be classified into different subtypes based upon DNA microarray profiles. The most recent study presented evidence for the existence of five different subtypes: normal breast-like, basal, luminal A, luminal B, and ERBB2(+). RESULTS: Based upon the analysis of 599 microarrays (five separate cDNA microarray datasets) using a novel approach, we present evidence in support of the most consistently identifiable subtypes of breast cancer tumor tissue microarrays being: ESR1(+)/ERBB2(-), ESR1(-)/ERBB2(-), and ERBB2(+ )(collectively called the ESR1/ERBB2 subtypes). We validate all three subtypes statistically and show the subtype to which a sample belongs is a significant predictor of overall survival and distant-metastasis free probability. CONCLUSION: As a consequence of the statistical validation procedure we have a set of centroids which can be applied to any microarray (indexed by UniGene Cluster ID) to classify it to one of the ESR1/ERBB2 subtypes. Moreover, the method used to define the ESR1/ERBB2 subtypes is not specific to the disease. The method can be used to identify subtypes in any disease for which there are at least two independent microarray datasets of disease samples.
format Text
id pubmed-1574316
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-15743162006-09-25 Discovery and validation of breast cancer subtypes Kapp, Amy V Jeffrey, Stefanie S Langerød, Anita Børresen-Dale, Anne-Lise Han, Wonshik Noh, Dong-Young Bukholm, Ida RK Nicolau, Monica Brown, Patrick O Tibshirani, Robert BMC Genomics Research Article BACKGROUND: Previous studies demonstrated breast cancer tumor tissue samples could be classified into different subtypes based upon DNA microarray profiles. The most recent study presented evidence for the existence of five different subtypes: normal breast-like, basal, luminal A, luminal B, and ERBB2(+). RESULTS: Based upon the analysis of 599 microarrays (five separate cDNA microarray datasets) using a novel approach, we present evidence in support of the most consistently identifiable subtypes of breast cancer tumor tissue microarrays being: ESR1(+)/ERBB2(-), ESR1(-)/ERBB2(-), and ERBB2(+ )(collectively called the ESR1/ERBB2 subtypes). We validate all three subtypes statistically and show the subtype to which a sample belongs is a significant predictor of overall survival and distant-metastasis free probability. CONCLUSION: As a consequence of the statistical validation procedure we have a set of centroids which can be applied to any microarray (indexed by UniGene Cluster ID) to classify it to one of the ESR1/ERBB2 subtypes. Moreover, the method used to define the ESR1/ERBB2 subtypes is not specific to the disease. The method can be used to identify subtypes in any disease for which there are at least two independent microarray datasets of disease samples. BioMed Central 2006-09-11 /pmc/articles/PMC1574316/ /pubmed/16965636 http://dx.doi.org/10.1186/1471-2164-7-231 Text en Copyright © 2006 Kapp et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Kapp, Amy V
Jeffrey, Stefanie S
Langerød, Anita
Børresen-Dale, Anne-Lise
Han, Wonshik
Noh, Dong-Young
Bukholm, Ida RK
Nicolau, Monica
Brown, Patrick O
Tibshirani, Robert
Discovery and validation of breast cancer subtypes
title Discovery and validation of breast cancer subtypes
title_full Discovery and validation of breast cancer subtypes
title_fullStr Discovery and validation of breast cancer subtypes
title_full_unstemmed Discovery and validation of breast cancer subtypes
title_short Discovery and validation of breast cancer subtypes
title_sort discovery and validation of breast cancer subtypes
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1574316/
https://www.ncbi.nlm.nih.gov/pubmed/16965636
http://dx.doi.org/10.1186/1471-2164-7-231
work_keys_str_mv AT kappamyv discoveryandvalidationofbreastcancersubtypes
AT jeffreystefanies discoveryandvalidationofbreastcancersubtypes
AT langerødanita discoveryandvalidationofbreastcancersubtypes
AT børresendaleannelise discoveryandvalidationofbreastcancersubtypes
AT hanwonshik discoveryandvalidationofbreastcancersubtypes
AT nohdongyoung discoveryandvalidationofbreastcancersubtypes
AT bukholmidark discoveryandvalidationofbreastcancersubtypes
AT nicolaumonica discoveryandvalidationofbreastcancersubtypes
AT brownpatricko discoveryandvalidationofbreastcancersubtypes
AT tibshiranirobert discoveryandvalidationofbreastcancersubtypes